azacitidine has been researched along with Anemia in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (17.86) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (28.57) | 29.6817 |
| 2010's | 8 (28.57) | 24.3611 |
| 2020's | 7 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hisasue, M; Neo, S; Tanaka, M | 1 |
| Bazinet, A; Bravo, GM | 1 |
| Chan, G; Cortes, JE; DiRienzo, CG; Dombret, H; Jeyakumar, D; Jou, E; Liu, X; Ma, W; Mayer, J; Merchant, A; Montesinos, P; Novak, J; O'Brien, T; Robak, T; Roh, W; Sekeres, MA; Shaik, N; Taussig, DC; Tomlinson, B; Wang, J | 1 |
| Petzer, V; Wolf, D | 1 |
| Dasanu, CA; Lerner, J; Michel, M | 1 |
| Bowen, D; Cargo, C; Culligan, D; Enright, H; Green, S; Ingram, W; Jones, GL; Kell, J; Killick, SB; Krishnamurthy, P; Kulasekararaj, A; Mills, J; Mufti, G; Payne, EM; Quek, L; Raghavan, M; Stanworth, SJ; Sternberg, A; Wiseman, DH | 1 |
| Bailey, R; Beach, CL; Chevassut, T; Döhner, H; Dombret, H; Figuera-Alvarez, A; Hiwase, D; La Torre, I; Montesinos, P; Musso, M; Pierdomenico, F; Pocock, C; Ravandi, F; Roboz, GJ; Safah, H; Sayar, H; Selleslag, D; Skikne, B; Sohn, SK; Tse, W; Wei, AH; Zhong, J | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Bailen, A; Calderon, C; Casaño, FJ; Falantes, J; Hermosin, L; Hernandez-Mohedo, F; Hernández-Rivas, JM; Hernandez-Sanchez, JM; Labrador, M; Lumbreras, E; Medina Perez, A; Sanchez-Garcia, J; Serrano, J; Solé Rodriguez, M; Torres-Sabariego, A; Vahí, M | 1 |
| Kiselev, P; Ma, X; Scott, BL; Steensma, DP; Sugrue, MM; Swern, AS | 1 |
| Gattermann, N; Germing, U; Kaivers, J; Kobbe, G; Kündgen, A; Schroeder, T | 1 |
| Li, J; Liu, J; Su, C; Tong, X; Zheng, D; Zhou, Z | 1 |
| Stahl, M; Zeidan, AM | 1 |
| Cosler, LE; Ferro, SA; Greenberg, PL; Lyman, GH | 1 |
| Becherer, K; Caldwell, C; Diaz-Arias, A; Feldman, M; Golda, N | 1 |
| Harigae, H; Yokoyama, H | 1 |
| Lachs, MS; Ritchie, EK | 1 |
| Bauer, K; Brillant, C; Engert, A; Herbst, C; Kluge, S; Monsef, I; Skoetz, N | 1 |
| Chan, EM; Chan, RJ; Cripe, LD; Hood, D; Hui, CL; Kohlbacher, KJ; Nabinger, SC; Orschell, CM; Plett, A; Sampson, C; Sayar, H; Walter, A; West, ES; Wu, J; Yang, Z; Yu, Z | 1 |
| Evans, C; Gryn, J; Lister, J; Meisner, D; Raymond, JM; Sbeitan, I; Shadduck, RK; Srodes, C; Zeigler, ZR | 1 |
| Sumida, KN; Suwanawiboon, B | 1 |
| Thomas, ML | 1 |
| Ozawa, K | 1 |
| Fu, MF; Knapp, MS; Knitter, G; Papayannopoulou, T; Stamatoyannopoulos, G; Torrealba-de Ron, AT | 1 |
| Beardsley, GP; Letvin, NL; Linch, DC; McIntyre, KW; Nathan, DG | 1 |
| Galanello, R; Papayannopoulou, T; Stamatoyannopoulos, G; Veith, R | 1 |
| Constantoulakis, P; Papayannopoulou, T; Stamatoyannopoulos, G | 1 |
| Dautenhahn, AG; Roth, RC; Veith, R | 1 |
7 review(s) available for azacitidine and Anemia
| Article | Year |
|---|---|
New Approaches to Myelodysplastic Syndrome Treatment.
Topics: Anemia; Antineoplastic Agents; Azacitidine; Humans; Lenalidomide; Myelodysplastic Syndromes; Quality of Life | 2022 |
Novel therapies in low- and high-risk myelodysplastic syndrome.
Topics: Activin Receptors, Type II; Anemia; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Erythrocyte Transfusion; Hematinics; Humans; Immunoglobulin Fc Fragments; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Oligonucleotides; Prognosis; Recombinant Fusion Proteins; Risk Assessment; Stem Cell Transplantation; Sulfonamides; Thalidomide; Thrombopoietin; Transplantation, Homologous | 2019 |
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
Topics: Anemia; Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 5; Disease Progression; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2017 |
[Management of anemia and bone marrow hypoplasia in the treatment of myeloid leukemia].
Topics: Anemia; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Bone Marrow Diseases; Clinical Trials as Topic; Decitabine; Drug Design; Erythrocyte Transfusion; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Platelet Transfusion; Practice Guidelines as Topic | 2009 |
5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures.
Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Erythropoietin; Hematopoietic Cell Growth Factors; Humans; Male; Myelodysplastic Syndromes; Thrombocytopenia | 2004 |
Strategies for achieving transfusion independence in myelodysplastic syndromes.
Topics: Anemia; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Drug Costs; Erythrocyte Transfusion; Erythropoietin; Health Services Needs and Demand; Humans; Immunosuppressive Agents; Informed Consent; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Quality of Life; Thalidomide; Treatment Outcome | 2007 |
[Pathophysiology, diagnosis and treatment of anemia].
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Thalidomide; Triazoles | 2008 |
4 trial(s) available for azacitidine and Anemia
| Article | Year |
|---|---|
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Nausea | 2023 |
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Disease Management; Female; Gastrointestinal Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Placebo Effect; Remission Induction; Thrombocytopenia | 2021 |
Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia.
Topics: Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Prognosis; Prospective Studies; Survival Rate | 2018 |
Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group.
Topics: Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; bcl-X Protein; Erythroid Precursor Cells; Erythropoiesis; Erythropoietin; Female; Flow Cytometry; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis | 2011 |
17 other study(ies) available for azacitidine and Anemia
| Article | Year |
|---|---|
A cat with myelodysplastic syndrome by administration of the methylation inhibitor Azacytidine.
Topics: Anemia; Animals; Azacitidine; Cat Diseases; Cats; Female; Leukopenia; Methylation; Myelodysplastic Syndromes | 2022 |
[Recent findings in myelodysplastic syndrome].
Topics: Anemia; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis | 2023 |
5-azacitidine reversing "spent" phase polycythemia vera back to proliferative phase and need for phlebotomy.
Topics: Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Female; Humans; Myeloproliferative Disorders; Phlebotomy; Polycythemia Vera | 2020 |
British Society for Haematology guidelines for the management of adult myelodysplastic syndromes.
Topics: Adult; Anemia; Antineoplastic Agents; Azacitidine; Blood Transfusion; Decitabine; Disease Management; Hematinics; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Iron Chelating Agents; Myelodysplastic Syndromes; Neutropenia; Thrombocytopenia | 2021 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.
Topics: Aged; Aged, 80 and over; Anemia; Azacitidine; Databases, Factual; Decitabine; Electronic Health Records; Enzyme Inhibitors; Female; Hematinics; Humans; Immunologic Factors; Iron Chelating Agents; Lenalidomide; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Proportional Hazards Models; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; United States | 2018 |
Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia.
Topics: Adult; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Decitabine; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Remission Induction; Thrombocytopenia; Treatment Outcome | 2015 |
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Topics: Anemia; Antineoplastic Agents; Azacitidine; Cost of Illness; Costs and Cost Analysis; Darbepoetin alfa; Decision Support Techniques; Deferoxamine; Drug Costs; Drug Therapy; Epoetin Alfa; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Recombinant Proteins; Siderophores; Thalidomide; United States | 2008 |
Neutrophilic panniculitis associated with myelodysplastic syndrome with abnormal nuclear forms.
Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Cell Nucleus Shape; Chelation Therapy; Erythropoietin; Granulocyte Colony-Stimulating Factor; Humans; Male; Myelodysplastic Syndromes; Neutrophils; Panniculitis | 2009 |
Management of myelodysplastic syndromes in the geriatric patient.
Topics: Aged; Anemia; Antineoplastic Agents; Azacitidine; Decitabine; Erythrocyte Transfusion; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2009 |
Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Bleomycin; Chlorambucil; Controlled Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Exercise; Hematinics; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Myelodysplastic Syndromes; Nitrogen Mustard Compounds; Prednisone; Procarbazine; Quality of Life; Randomized Controlled Trials as Topic; Vinblastine; Vincristine | 2010 |
Treatment of myelodysplastic syndromes with 5-azacytidine.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Azacitidine; Blood Transfusion; Female; Humans; Leukocytes; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2002 |
Perturbations in the erythroid marrow progenitor cell pools may play a role in the augmentation of HbF by 5-azacytidine.
Topics: Anemia; Animals; Azacitidine; Bloodletting; Bone Marrow Cells; Cell Count; Colony-Forming Units Assay; Erythrocytes; Erythropoiesis; Fetal Hemoglobin; Fluorescent Antibody Technique; Globins; Hematopoietic Stem Cells; Hemoglobin A; Male; Papio; Reticulocytes | 1984 |
Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea.
Topics: Anemia; Animals; Azacitidine; Bloodletting; DNA; Erythrocyte Count; Fetal Hemoglobin; Globins; Hydroxyurea; Macaca fascicularis; Methylation; Transcription, Genetic | 1984 |
Hb F production in stressed erythropoiesis: observations and kinetic models.
Topics: Anemia; Animals; Azacitidine; Cell Cycle; Cell Differentiation; Cytarabine; Erythropoiesis; Fetal Hemoglobin; Hematopoietic Stem Cells; Humans; Hydroxyurea; Kinetics; Models, Biological; Time Factors; Transcription, Genetic | 1985 |
alpha-Amino-N-butyric acid stimulates fetal hemoglobin in the adult.
Topics: Adult; Aminobutyrates; Anemia; Animals; Azacitidine; Drug Synergism; Erythropoiesis; Female; Fetal Hemoglobin; Gene Expression Regulation; Globins; Hematopoietic Stem Cells; Humans; Male; Papio | 1988 |
Methotrexate stimulates fetal hemoglobin production in anemic baboons.
Topics: Anemia; Animals; Azacitidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythrocyte Count; Fetal Hemoglobin; Hematocrit; Methotrexate; Papio; Reticulocytes | 1989 |